A Review of Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder
1988; Slack Incorporated (United States); Volume: 18; Issue: 6 Linguagem: Inglês
10.3928/0048-5713-19880601-12
ISSN1938-2456
AutoresSuck Won Kim, Maurice W. Dysken,
Tópico(s)Treatment of Major Depression
ResumoPsychopharmacology UpdateA Review of Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder Suck Won Kim, MD, , and , MD Maurice W Dysken, MD, , MD Suck Won Kim, MD and Maurice W Dysken, MD Published Online:June 01, 1988https://doi.org/10.3928/0048-5713-19880601-12PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Lopes-Ibor II: Ensayo clinico de la monochlorimipramina. Read at the Fourth World Congress of Psychiatry. Madrid 1966. Google Scholar2. Fernandez CE. Lopez-lbor JJ: Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso Esp Neurol Psiquiatr 1967: 26:119-147. Google Scholar3 . Guyotat J. Favre-Tissot M , Marie-Gardine M: A clinical triai with a new antidepressant G34586. Presented at the CR Congress of Psychiatry and Neurology. Dijon. 1967. Masson, Paris 1968: pp 717-772. Google Scholar4. De Voxvrie G Van: Anafranil w (G34586) in obsessive neurosis. Acta Neurol BeIg 1968; 68:787-792. Google Scholar5. Thoren P. Asberg M. Cronholm B, et al: Clomipramine treatment of obsessivecompulsive disorder: I. A controlled clinical trial. Arch Gen Psychiatry 1980: 37:1281-1285. Google Scholar6. Thoren P, Asberg M. Bertilsson L, et at: Clomipramine treatment of obsessive compulsive disorder. II. Biochemical aspects. Arch Gent Psychiatry 1980; 37:1289-1294. Google Scholar7. Insel T. Murphy DL. Cohen RM. et al: Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983: 40:605-612. Google Scholar8. Robins LN. Heizer JE, Weissman MM. et al: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41:949-958. Google Scholar9. Hyttel J: Citalopram- pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog NeuropsvdwpharmacolBiol Psychiatry 1982; 6:277-295. Google Scholar10. Benfield P. Ward A: Fluvoxamine - A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drags 1986; 32:313-334. Google Scholar11. Stark P, Fuller RW, Wong DT: The pharmacologic proiile of fluoxetine. J Clin Psychiatrv 1985; 46(suppl 3. sec 2):7-13. Google Scholar12. Koe BK. Weissman A, Welch WM. et ah Sertraline. Is. 4s-N-methyi-4-(3,4dichlorophenyl)-1,2,34-tetrahydro-1naphthylamine. a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983; 226:686-700. Google Scholar13. Meyer V: Modification of expectations in cases with obsessional rituals. Behav Res Ther 1966; 4:273-280. Google Scholar14. Marks IM: Review of behavioral psychotherapy: I. Obsessive-compulsive disorders. Am J Psychiatry 1981: 138:584-592. Google Scholar15. Foa EB, Goldstein A: Continuous exposure and complete response prevention in the treatment of obsessive-compulsive neurosis. Behavior Therapy 1978: 9:821-829. Google Scholar16. Rachman S). Hodgson R): Obsessions and Compulsions. Englewood Cliffs, NJ. Prentice-Hall. 1980. Google Scholar17. Perse T. Creisi JH. Jefferson JW. et al: Fluvoxamine treatment of obsessive-compulsive disorder. Am f Psychiatry 1987; 144:1543-1548. Google Scholar18. Price LH. Goodman WK. Charney DS, et al: Treatment of severe obsessive compulsive disorder with fluvoxamine. Am J Psychiatry 1987: 144:1059-1061. Google Scholar19. Turner SM. Jacob RG. Beidel DC. et al: Fluoxetine treatment of obsessivercompulsive disorder. J Clin Psychopharmacol 1985; 5:207-212. Google Scholar20. Fontaine R. Chouinard G; An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1986: 6:98-101. Google Scholar21. Carlsson A, Corrodi H. Fuxe K. et al: Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methylalpha-ethyl-metatyraminc. Eur J Pharmacol 1969; 5:357-366. Google Scholar22. Waxman D: A clinical trial of clomipramine and diazepam in the treatment of phobic and obsessional illness. J Int Med Res 1977; 5(suppl 5):99-110. Google Scholar23. Karabanow O: Double blind controlled study in phobias and obsessions. J Int Med Res 1977; 5(suppl 51:42-48. Google Scholar24. Gringras M. Dobst ChB: An uncontrolled trial of clomipramine (Anafranil5) in the treatment of phobic and obsessional states in general practice. J Int Med Res 1977; 5(suppl 5): 111-115. Google Scholar25. Amin MM: Clomipramine (Anafranil™) and behavior therapy in obsessive-compulsive and phobic disorders. J Int Med Res 1977; 5(suppl 51:33-37. Google Scholar26. Allen JJ, Rack PH: Changes in obsessivecompulsive patients as measured by the Leyton Inventory before and after treatment with clomipramine. Scott Med J 1975; 20:41-44. Google Scholar27. Yaryura-Tobias JA. Neziroglu F: The action of chlorimipramine in obsessivecompulsive neurosis: A pilot study. Curr Ther Res 1975: 17:111-116. Google Scholar28. Wyndowe J. Solyom L, Ananth J: Anafranil '" in obsessive-compulsive neurosis. Curr Ther Res 1975; 18:611-617. Google Scholar29. Ananth J., Solyom L. Bryntwick S, et al: Chlorimipramine therapy for obsessive compulsive neurosis. Am J Psychiatry 1979; 136:700-701. Google Scholar30. Cooper J: The Leyton Obsessional Inventory. Psychol Med 1970; 1:48-64. Google Scholar31. Singh AN, Saxena B: Clomipramine (Anafranil"1) in depressive patients with obsessive neurosis. J Int Med Res 1977; 5(suppl 5):25-32. Google Scholar32. Rapoport J, Elkins R. Mikkelsen E, et al: Clinical controlled trial of chlorimipramine in adolescents with obsessive-compulsive disorder. PsychoPharmacol Bull 1980; 16:61-63. Google Scholar33. Prasad A: Efficacy of trazodone as an antiob sessional agent. Neuropsyehobiology 1986; 15(suppl 1):19-21. Google Scholar34. Prasad A: A double blind study of imipramine versus zimelidine in treatment of obsessive-compulsive neurosis. Pharmacopsychiatry 1984; 17:61-62. Google Scholar35. Flament MF. Rapoport JL. Berg CJ, et al: Clomipramine treatment of childhood obsessive-compulsive disorder. A double blind controlled study. Arch Gen Psychiatry 1985; 42:977-983. Google Scholar36. Marks IM. Stern RS. Mawson D. et al: Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980: 136:1-25. Google Scholar37. Mawson D. Marks IM. Ramm L: Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Two year follow-up and further findings. Br J Psychiatry 1982; 140:11-18. Google Scholar38. Volavka J, Neziroglu F, Yaryura-Tobias JA: Clomipramine and Imipramine in obsessive-compulsive disorder. Psychiatry Res 1985; 14:83-91. Google Scholar39. Mavissakalian M. Turner SM. Michelson L, el a): Tricyclic antidepressants in obsessive-compulsive disorder: Antiobsessional or antidepressant agents? II. Am J Psychiatry 1985; 142:572-576. Google Scholar40. Mavissakalian M. Michelson L: Tricyclic antidepressants in obsessive-compulsive disorder: Antiobsessionai or antidepressant agents? J Nerv Ment Dis 1983; 171:301-506. Google Scholar41. Yaryura-Tobias JA. Neziroglu F. Bergman L: Chlorimipramine. for obsessive-compulsive neurosis: An organic approach. Curr Ther Res 1976: 20:541-548. Google Scholar42. Ananth J. Pecknold IC Van Der Steen N. et al: Double blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuro psychopharmacol Biol Psychiatry 1981 5:257-262. Google Scholar43. Ananth J. Van Der Steen N: Systematic studies in the treatment of obsessive-compulsive neurosis with tricyclic antidepressants. Curr Ther Res 1977; 21:495-501. Google Scholar44. Stern RS, Marks IM. Mawson D, et al: Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. Br J Psychiatry 1980: 156:161-166. Google Scholar45. Ananth J: Clomipramine: An antiobsessive drug. Can J Psychiatry 1986; 31:253-258. Google Scholar46. Waxman D: An investigation into the use of Anafranil™ in phobic and obsessional disorders. Scott Medi 1975; 20:61-66. Google Scholar47. Anafranil™ Investigator Brochure. Page 51. Ciba-Geigy, Nov. 1986. Google Scholar48. Wamsley JK. Byerley WF. McCabe RT. et al: Receptor alterations associated with serotonergic agents: An autoradiographic analysis. J Clin Psychiatry 1987; 48(suppl 31:19-25. Google Scholar49. Sulser F: Serotonin-norepinephrine receptor interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. J Clin Psychiatry 1987: 48(suppl 3): 12-18. Google Scholar50. Lemberger L. Bergstrom RF. Wolen RL, et at: Fluoxetine: Clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46(suppl 3, sec 21:14-19. Google Scholar51. Goudie AJ. Thornton EW. Wheeler TJ: Effects of Lilly 1 10140. a specific inhibitor of 5-hydroxytryptamine uptake, on food intake and on 5-hydroxytryptophaninduced anorexia. Evidence for serotonergic inhibition of feeding. J Pharm Pharmacol 1976: 28:318-320. Google Scholar52. Wernicke IF: The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985: 46:59-67. Google Scholar53. Ross SB. Renyi AL: Inhibition of the neuronal uptake of 5-hydroxytryptamine and noradrenaline in rat brain by (Z) and (E)-3-(4-bromophenyl)-N.N-dimethyl3-(3-pyridyl) allylamines and their secondary analogues. Neuropharmacology 1977: 16:57-63. Google Scholar54. Bertilsson L, Tuck IR. Siwers B: Biochemical effects of zimelidine in man. Eur J Clin Pharmacol 1980; 18:483-487. Google Scholar55. Committee on Safety of Medicines (United Kingdom): Zimelidine. Current problems No 11. 1983. p 1. Google Scholar56. Kahn RS, Westenberg HGM, Jolies J: Zimelidine treatment of obsessive-compulsive disorder: Biological and neuropsychological aspects. Acta Psych tat r Scand 1984; 69:259-261. Google Scholar57. Insel TR. Mueller EA. Aiterman I. et al: Obsessive-compulsive disorder and serotonin: Is there a connection? Biol Psychiatry 1985: 20:1174-1188. Google Scholar58. Nilsson BS: Adverse reactions in connection with zimelidine treatment - A review. Acta Psyehiatr Scand 1983; 68(suppl 308):II5-1I9. Google Scholar59. Baxter Jr LR: Two cases of obsessivecompulsive disorder with depression responsive to trazodone. J Nerv Meni Dis 1985; 173:432-433. Google Scholar60. Lydiaid BR: Obsessive-compulsive disorder successfully treated with trazodone. Psychosomatics 1986; 27:858-859. Google Scholar61. Klein DF. Fink M: Psychiatric reaction pattern to Imipramine. Am J Psychiatry 1962: 119:4-32-438. Google Scholar62. Klein DF; Delineation of two drugresponsive anxiety syndromes. Psychopharmacologia 1964: 5:397-408. Google Scholar63. Bunney WE, Davis JM: Norepinephrine in depressive reactions. Arch Gen Psychiatry 1965; 13:483-494. Google Scholar64. Schiidkraut H, Kety SS: Biogenic amines a nd emotion . Science 1967;156:21-30. Google Scholar65. Sulser F: Update on neuroreceptor mechanisms and their implication for the pharmacotherapy of affective disorders. J Clin Psychiatry 1986; 47(suppl).13-l8. Google Scholar66. Beaumont G: A new rating scale for obsessional and phobic states. Scott Med J 1975; 20(suppl):25-32. Google Scholar67. Deroga tis LR. Lipman RS. Covi L: SCL-90; An outpatient psychiatric rating scale: Preliminary report. Psychopharmacol Bull 1973; 9: 13-28. Google Scholar68. Asberg M. Montgomery SA. Perris C et al: A comprehensive psychopathological rating scale. Acta Psyehiatr Scand 1978; suppl 271, pp 5-27. Google Scholar69. Berg Cl, Rapoport JL, Flament M: The Leyton obsessional inventory- child version. J Am Acad Child Psychiatry 1986; 25(1):84-91. Google Scholar70. Goodman WK. Rasmussen SA, Mazure CM, et al: Measurement of treatment response in OCD: Use and validation of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). American College of Neuropsychopharmacology Annual Meeting, 1987; 130. Google Scholar Previous article Next article FiguresReferencesRelatedDetails Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download
Referência(s)